The COVID-19 virus is mutating rapidly. As subvariants like BA.4 and BA.5 emerge, we must act fast to curb the pandemic. Vaccination is the most effective way to control epidemic, but the protection it offers declines as the virus evolves. Predicting vaccine effectiveness in a short time frame is key to winning this battle. CUHK researchers have developed a bioinformatics platform that can provide a snapshot of vaccine effectiveness in real time, instead of it taking months.
A new chapter is opening in cancer immunotherapy. A first-in-human clinical trial of CRISPR technology to treat late stage lung cancer has proved safe by a CUHK joint research. T-Cells of advanced condition patients have been extracted, gene edited and reinfused as potential fighters against cancer cells.